Covid 19 and Endocrinology

Diabetes plays a significant role in this phenotype because it is one of the most common comorbidities linked to COVID-19 severity and mortality. Careful management, including treatment changes, may be required to protect our patients from the most serious effects of COVID-19, whether they have diabetes or are hospitalised with COVID-19, as well as patients with SARS-CoV-2-induced recently onset diabetes. Obesity raises vulnerability to SARS-CoV-2 and the chance of a negative COVID-19 result.

    Related Conference of Covid 19 and Endocrinology

    November 27-28, 2024

    14th World Congress on Endocrinology and Diabetes

    Paris, France
    February 24-25, 2025

    34th European Diabetes Congress

    London, UK
    March 10-11, 2025

    4th Global Summit on Physiology and Metabolism of Thyroid

    Singapore City, Singapore
    March 17-18, 2025

    5th European Endocrinology and Diabetes Congress

    Paris, France
    April 10-11, 2025

    5th World Congress on Endocrine and Diabetes

    Dubai, UAE
    April 10-11, 2025

    4th International Summit on Hormonal Disorders

    Dubai, UAE
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Aix-en-Provence, France

    Covid 19 and Endocrinology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in